BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway.
about
The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemiaClinical implications of the molecular genetics of chronic lymphocytic leukemiaThe pathogenesis of chronic lymphocytic leukemiaFusion toxin BLyS-gelonin inhibits growth of malignant human B cell lines in vitro and in vivoMicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemiaUsing high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitorsB-cell CLL/lymphoma 10 (BCL10) is required for NF-kappaB production by both canonical and noncanonical pathways and for NF-kappaB-inducing kinase (NIK) phosphorylation.Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLLA functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapyConstitutive non-canonical NFkappaB signaling in pancreatic cancer cellsGene cloning, expression and functional characterization of a proliferation-inducing ligand (APRIL) from hedgehog (Erinaceus europaeus).B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia.STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells.The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignanciesRequirements for innate immune pathways in environmentally induced autoimmunity.CD137 is induced by the CD40 signal on chronic lymphocytic leukemia B cells and transduces the survival signal via NF-κB activationOSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cellsTACI expression and signaling in chronic lymphocytic leukemiaNeutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemiaMicroscale functional cytomics for studying hematologic cancersTACI deficiency leads to alternatively activated macrophage phenotype and susceptibility to Leishmania infection.IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival.Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L.Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agentsEmerging role of kinase-targeted strategies in chronic lymphocytic leukemia.B-cell maturation antigen is modified by a single N-glycan chain that modulates ligand binding and surface retention.Tailoring of chronic lymphatic leukemia therapyA proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activationPhase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemiaNF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia.NF-kappaB as a therapeutic target in chronic lymphocytic leukemia.Inflammation and survival pathways: chronic lymphocytic leukemia as a model system.Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia.Molecular genetics of high-risk chronic lymphocytic leukemia.PPI-G4 Glycodendrimers Upregulate TRAIL-Induced Apoptosis in Chronic Lymphocytic Leukemia Cells.Modeling the chronic lymphocytic leukemia microenvironment in vitro.
P2860
Q26775506-91EDC949-1809-4531-AFAB-3B575B0E1AC4Q26830955-B7DDDA85-E95F-4075-B8ED-D913E9F34703Q27025715-CDAF12CA-E459-43E3-8EF4-017A15DE7674Q27314650-970CFEF1-C93C-4125-88B4-60A1B3EB4A68Q28241703-366F396A-D399-420D-889F-D5002857590EQ33566747-5F275AC5-4302-4AB7-96EC-EEEA84348516Q33581388-8F265772-D2B6-45C6-9E72-02087CE4A91DQ33714712-C11DF102-CB95-4644-9B3E-56E09969E80FQ33891940-97663033-3F07-40E4-9A6E-F884BFC2DB88Q33997214-0F474F05-7581-416C-AC8C-E59B15CE24ECQ34020276-1507835C-393F-432A-A3E7-88B01E2C1306Q34021737-0E7ADE4F-C70C-458F-A927-87910810B273Q34128107-A7AEB729-8DA6-4AF2-855E-3EA1B476DBE8Q34279007-F3E119CA-A110-41DA-AB84-BFF34BE01824Q34419599-10A9950B-BA83-4470-B91A-43E23D2A8DF9Q34542102-0C659AF1-D1FA-4921-88D9-6BB2DB9CF589Q34619806-0A664B10-46A4-40CE-B511-BFE20709D99EQ34655526-F67E153F-3AC8-4EC3-8CB2-A7C5BB01A83EQ34734190-47F0CA9C-824D-40B3-9D77-6CF69C85F5A0Q34876742-47842E4E-A846-4B23-ADCC-D98D68034FBAQ35534809-E1928846-05BC-4B23-BF12-763C42A463ABQ35566828-48966989-F619-4824-8F5C-90E7643F3BAAQ35791336-D34C3AC8-4358-43B1-81AC-53C39F65206CQ35849287-D5E40710-4FB7-434D-9D57-55A04F715C94Q35910201-93ABE2FC-9F53-40C4-9ABA-2506ABAE1058Q35941404-62B0E893-85D8-455F-9ECF-A01432C65B17Q36016378-68BCBF73-BE3C-48A2-B02C-615CE476D5D9Q36293814-B8DFB528-D5BE-493F-924E-2F397182CD78Q36462375-D3743004-0BBE-4971-9AE0-26E723A89ADFQ36990979-0CC6A5E4-58A5-4F10-84F4-DCBB1246C38FQ37127542-46A69541-FFF8-4D13-8387-70BEF0A880BFQ37201980-DE2724F6-4F93-49EE-83DF-76BF7E882220Q37257024-7E528FC0-EB02-4BF0-8CFF-9DAB38256263Q37605861-B3DE575C-5FB3-4246-BC6F-34871C732E29Q37690750-1D48076B-71FA-4575-AD49-D3D28AFF0F98Q37778876-0752343A-404D-4D05-A118-605DC2626AB3Q37971736-B2B0C6AD-83C2-4BF2-A183-6E82743A3DA4Q38065304-B0C4E350-0541-44BD-9734-705F13E59652Q38780337-E89D65C8-57C2-4AD2-A3C1-7A138C220634Q38984569-3262EC37-C616-4CED-B65B-6E3E59FDDDDD
P2860
BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
BAFF and APRIL support chronic ...... e canonical NF-kappaB pathway.
@en
BAFF and APRIL support chronic ...... e canonical NF-kappaB pathway.
@nl
type
label
BAFF and APRIL support chronic ...... e canonical NF-kappaB pathway.
@en
BAFF and APRIL support chronic ...... e canonical NF-kappaB pathway.
@nl
prefLabel
BAFF and APRIL support chronic ...... e canonical NF-kappaB pathway.
@en
BAFF and APRIL support chronic ...... e canonical NF-kappaB pathway.
@nl
P2093
P2860
P1433
P1476
BAFF and APRIL support chronic ...... e canonical NF-kappaB pathway.
@en
P2093
Danelle F James
Howard B Cottam
Mitsufumi Nishio
Tetsuya Fukuda
Thomas Enzler
Thomas J Kipps
Tomoyuki Endo
P2860
P304
P356
10.1182/BLOOD-2006-06-027755
P407
P577
2006-09-14T00:00:00Z